PA8B Stock Overview
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Paion AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.002 |
| 52 Week High | €0.075 |
| 52 Week Low | €0.002 |
| Beta | 1.49 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.33% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PA8B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | n/a | -1.5% | 1.9% |
| 1Y | n/a | -23.6% | 4.6% |
Return vs Industry: Insufficient data to determine how PA8B performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how PA8B performed against the German Market.
Price Volatility
| PA8B volatility | |
|---|---|
| PA8B Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PA8B's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PA8B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 64 | Tilmann Bur | www.paion.com |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Paion AG Fundamentals Summary
| PA8B fundamental statistics | |
|---|---|
| Market cap | €2.70m |
| Earnings (TTM) | -€19.86m |
| Revenue (TTM) | €14.81m |
0.2x
P/S Ratio-0.1x
P/E RatioIs PA8B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PA8B income statement (TTM) | |
|---|---|
| Revenue | €14.81m |
| Cost of Revenue | €6.35m |
| Gross Profit | €8.46m |
| Other Expenses | €28.32m |
| Earnings | -€19.86m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 15, 2023
| Earnings per share (EPS) | -2.78 |
| Gross Margin | 57.15% |
| Net Profit Margin | -134.12% |
| Debt/Equity Ratio | -675.5% |
How did PA8B perform over the long term?
See historical performance and comparison